TELA Bio's Bold Legal Move
Becton, Dickinson & Company (NYSE: BDX) is facing serious allegations as TELA Bio, Inc. (NASDAQ: TELA) takes a stand against their alleged monopolistic practices in the hernia mesh market. The lawsuit claims that Becton Dickinson has been using its considerable power to suppress competition, leading to inflated costs for hospitals and limited choices for patients.
The Allegations Unveiled
The crux of the complaint is that Becton Dickinson has engaged in restrictive contracting practices that effectively shut out lower-cost alternatives favored by physicians. This lawsuit has garnered attention, especially with the publication of the full complaint which outlines how these practices are detrimental to both healthcare providers and patients.
Understanding the Market Dynamics
The lawsuit specifically addresses two critical segments of the hernia mesh market: permanent mesh and resorbable mesh. Permanent mesh is a widely used, cost-effective plastic option, while resorbable mesh, which integrates into the body, is used in more intricate surgical procedures.
Becton Dickinson reportedly dominates these markets, controlling approximately 65% of the U.S. permanent hernia mesh market by dollar share and around 77% of the resorbable segment. This significant market control enables them to exert undue influence over pricing and purchasing decisions within hospitals.
The Arrival of TELA Bio
In 2016, TELA Bio entered this competitive landscape with their innovative product, OviTex, which is a resorbable mesh made from sheep-derived extracellular matrix. Unlike Becton Dickinson’s Phasix, OviTex is priced 15% to 45% lower, appealing to both physicians and patients seeking cost-effective options.
According to the complaint, many physicians have shown a preference for OviTex due to its favorable balance of strength, absorption, and cost. Unfortunately, rather than competing on price or quality, Becton Dickinson allegedly leveraged its market power to maintain its own product's dominance.
Shining a Light on Contracting Practices
TELA Bio asserts that Becton Dickinson has implemented overlapping multi-year contracts with group purchasing organizations and hospitals to hinder the market entry of OviTex. These contracts purportedly connect discounts on Becton Dickinson’s products with the restriction of competitive resorbable mesh offerings, thereby maintaining their market share.
This tactic left TELA Bio struggling to gain recognition despite rising demand from physicians, while Becton Dickinson’s higher-priced Phasix maintained its stronghold in hospitals across the nation.
The Consequences for Patients
The impact of these monopolistic practices on patients is sobering. The lawsuit points to a specific incident where a surgeon was denied the use of OviTex due to hospital contracts with Becton Dickinson, tragically resulting in a patient’s serious decline and eventual death during surgery.
In light of these serious implications, TELA Bio is pursuing damages and aims for injunctive relief to restore fair competition and increase choices for both providers and patients in the hernia mesh market.
Interestingly, Becton Dickinson’s C.R. Bard division was previously ordered to pay $4.8 million related to claims surrounding their hernia repair mesh, and it currently faces over 30,000 additional lawsuits connected to their mesh products.
Price Action: TELA Bio's shares witnessed a rise of 1.75%, trading at $1.15 in premarket activity. Meanwhile, BDX stock closed at $196.74 recently.
Frequently Asked Questions
What is the core issue of the lawsuit?
The lawsuit centers around allegations that Becton Dickinson abused its market dominance to suppress competition and inflate prices in the hernia mesh market.
How does TELA Bio's product compare to Becton Dickinson's?
TELA Bio’s OviTex is priced significantly lower than Becton Dickinson's Phasix and is gaining favor among physicians for its clinical effectiveness.
What steps is TELA Bio taking in this lawsuit?
TELA Bio seeks damages, injunctive relief, and methods to restore competition in the hernia mesh market while increasing options for patients and providers.
What have been the recent developments regarding Becton Dickinson?
Recent developments include multiple lawsuits against Becton Dickinson’s C.R. Bard division related to hernia repair mesh complications, highlighting ongoing concerns in their practices.
How are the actions of Becton Dickinson affecting patients?
Patients reportedly suffered harm due to Becton Dickinson's contracting practices, which limited their access to potentially better and safer treatment options.
